Biomedical Engineering Reference
In-Depth Information
Cell culture
(Engineered CHO-DN2-3
Recovery of product-containing
extracellular fluid (centrifugation
or filtration)
α
3 cell
line)
Blue-sepharose dye affinity
chromatography
Hydroxylapatite chromatography
Ion exchange
(DEAE-sepharose)
Reverse-phase HPLC
Fill and freeze dry
Excipient addition
Figure 10.5
Schematic overview of the production of the EPO-based product 'Neorecormon'. Refer to text
for further details
In addition to enhancing erythropoiesis, EPO treatment also improves tolerance to exercise, as
well as a patient's sense of well-being. Furthermore, reducing/eliminating the necessity for blood
transfusions also reduces/eliminates the associated risk of accidental transmission of blood-borne
infectious agents, as well as the risk of precipitating adverse transfusion reactions in recipients. The
therapeutic spotlight upon EPO has now shifted to additional (non-renal) applications (Table 10.8).
Table 10.8
Some non-renal applications of EPO (refer to text for details)
Treatment of anaemia associated with chronic disease
Treatment of anaemia associated with cancer/chemotherapy
Treatment of anaemia associated with prematurity
To facilitate autologous blood donations before surgery
To reduce transfusion requirements after surgery
To prevent anaemia after bone marrow transplantation
Search WWH ::
Custom Search